Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Glaucoma, Retinal Disease, Healthy
Interventions: KOWA OCT Bi-µ, Optovue iVue 100; Device
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: X-Linked Retinitis Pigmentosa
Interventions: Not listed
Lead sponsor: Beacon Therapeutics; Industry
Eligibility: 6 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 3
States / cities: Durham, North Carolina • Portland, Oregon • Dallas, Texas

Conditions: Retinal Disease
Interventions: ICG loaded erythrocytes; Procedure
Lead sponsor: Northwell Health; Other
Eligibility: 40 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Macular Degeneration
Interventions: Proparacaine Ophthalmic, Tetracaine Ophthalmic, Lidocaine 4%, Lidocaine 2% Injectable Solution; Drug
Lead sponsor: Lahey Clinic; Other
Eligibility: 40 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Arlington, Massachusetts • Burlington, Massachusetts • Peabody, Massachusetts

Conditions: Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
Interventions: BS01, Sham procedure control; Biological · Other
Lead sponsor: Bionic Sight LLC; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Edison, New Jersey

Conditions: Retinitis Pigmentosa, Choroideremia, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy from Age-related Macular Degeneration, X-lined Retinoschisis, Retinal Dystrophies
Interventions: Not listed
Lead sponsor: Ray Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Irvine, California

Conditions: Diabetic Retinopathy
Interventions: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 64
States / cities: Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 59 more

Conditions: Stargardt Disease-1
Interventions: STG-001; Drug
Lead sponsor: Stargazer Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Phoenix, Arizona • Gainesville, Florida • Portland, Oregon + 2 more

Conditions: Retinal Vascular Disorder, Macular Degeneration
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 115 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Retinoblastoma
Interventions: Melphalan; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 4 Months and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Neovascular (Wet) Age-related Macular Degeneration
Interventions: SKG0106; Genetic
Lead sponsor: Skyline Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: Boston, Massachusetts • Katy, Texas • Norfolk, Virginia

Conditions: Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
Interventions: Free Eye Screenings, Enhanced Intervention, Usual Care; Other
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years and older
Enrollment: 906 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ptosis, Macular Degeneration, Ametropia
Interventions: Virtual Reality Headset; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions: Intravitreal Injection of Ultevursen, No intervention, will not receive any active study intervention; Drug · Other
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 8 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: San Francisco, California • Miami, Florida • Atlanta, Georgia + 7 more

Conditions: Retinitis Pigmentosa
Interventions: Object recognition subsystem; Device
Lead sponsor: Minnesota HealthSolutions; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration
Interventions: Everolimus, Ranibizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 4
States / cities: Beverly Hills, California • Sacramento, California • Denver, Colorado + 1 more

Conditions: Radiation Retinopathy, Macular Edema
Interventions: Aflibercept every 2 months, Aflibercept monthly; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: St Louis, Missouri • Houston, Texas

Conditions: Gyrate Atrophy
Interventions: Gene therapy; Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinal Disease
Interventions: Finasteride; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Age-related Wet Macular Degeneration
Interventions: CG-P5 peptide, Placebo, Aflibercept Injection [Eylea]; Drug
Lead sponsor: Caregen Co. Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Manchester, Connecticut • Deerfield Beach, Florida • Augusta, Georgia + 4 more

Conditions: Central Serous Chorioretinopathy
Interventions: rhuFab V2 [ranibizumab] ( Lucentis ); Drug
Lead sponsor: Vitreous -Retina- Macula Consultants of New York; Other
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Retinal Dystrophies
Interventions: Optical coherence tomography (OCT); Diagnostic Test
Lead sponsor: Institute of Molecular and Clinical Ophthalmology Basel; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: San Francisco, California • Miami, Florida • Pittsburgh, Pennsylvania

Conditions: Retinoblastoma
Interventions: vincristine, topotecan, filgrastim, PEG-filgrastim, carboplatin, focal therapy, etoposide, cyclophosphamide, MESNA, doxorubicin, enucleation, external beam radiation or proton beam radiation; Drug · Other · Procedure + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Glaucoma, Open-Angle
Interventions: Netarsudil Ophthalmic; Drug
Lead sponsor: University of the Incarnate Word; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100

Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

Erythrocyte Ghost Mediated Retinal Diagnosis

Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

Study of STG-001 in Subjects With Stargardt Disease

Ocular Imaging Study Using Advanced OCT

Intra-arterial Chemotherapy for Retinoblastoma

A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

Comparing Vision Tests in a Virtual Reality Headset to Existing Analogues

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Object Finder for a Retinal Prosthesis

The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration

Intravitreal Aflibercept Injection for Radiation Retinopathy

Gene Therapy for Gyrate Atrophy

Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

EyeConic: Qualification for Cone-Optogenetics

Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma

Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation